- Home
- KNDI vs VTYX Comparison
KNDI vs VTYX Comparison
Compare KNDI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- VTYX
- Stock Information
- Founded
- KNDI 2002
- VTYX 2018
- Country
- KNDI China
- VTYX United States
- Employees
- KNDI N/A
- VTYX N/A
- Industry
- KNDI Auto Manufacturing
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- KNDI Consumer Discretionary
- VTYX Health Care
- Exchange
- KNDI Nasdaq
- VTYX Nasdaq
- Market Cap
- KNDI 96.3M
- VTYX 154.9M
- IPO Year
- KNDI N/A
- VTYX 2021
- Fundamental
- Price
- KNDI $1.15
- VTYX $2.16
- Analyst Decision
- KNDI
- VTYX Buy
- Analyst Count
- KNDI 0
- VTYX 4
- Target Price
- KNDI N/A
- VTYX $11.33
- AVG Volume (30 Days)
- KNDI 98.2K
- VTYX 1.9M
- Earning Date
- KNDI 08-15-2025
- VTYX 08-07-2025
- Dividend Yield
- KNDI N/A
- VTYX N/A
- EPS Growth
- KNDI N/A
- VTYX N/A
- EPS
- KNDI N/A
- VTYX N/A
- Revenue
- KNDI $127,569,613.00
- VTYX N/A
- Revenue This Year
- KNDI N/A
- VTYX N/A
- Revenue Next Year
- KNDI N/A
- VTYX N/A
- P/E Ratio
- KNDI N/A
- VTYX N/A
- Revenue Growth
- KNDI 3.21
- VTYX N/A
- 52 Week Low
- KNDI $0.89
- VTYX $0.78
- 52 Week High
- KNDI $2.07
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- KNDI 54.64
- VTYX 51.25
- Support Level
- KNDI $1.09
- VTYX $1.95
- Resistance Level
- KNDI $1.16
- VTYX $2.51
- Average True Range (ATR)
- KNDI 0.07
- VTYX 0.16
- MACD
- KNDI 0.01
- VTYX -0.06
- Stochastic Oscillator
- KNDI 74.86
- VTYX 36.61
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.